See more : PBT Group Limited (PBG.JO) Income Statement Analysis – Financial Results
Complete financial analysis of Ultimovacs ASA (ULTI.OL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ultimovacs ASA, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shashijit Infraprojects Limited (SHASHIJIT.BO) Income Statement Analysis – Financial Results
- NGS Group AB (publ) (NGS.ST) Income Statement Analysis – Financial Results
- Taokaenoi Food & Marketing Public Company Limited (TKN.BK) Income Statement Analysis – Financial Results
- Gi Group Poland S.A. (GIG.WA) Income Statement Analysis – Financial Results
- The Caldwell Partners International Inc. (CWL.TO) Income Statement Analysis – Financial Results
Ultimovacs ASA (ULTI.OL)
About Ultimovacs ASA
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.77M | 2.65M | 2.70M | 2.72M | 2.06M | 601.00K | 534.00K | 489.00K |
| Gross Profit | -2.77M | -2.65M | -2.70M | -2.72M | -2.06M | -601.00K | -534.00K | -489.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 123.83M | 95.18M | 96.74M | 64.66M | 35.53M | 16.96M | 12.83M | 12.14M |
| General & Administrative | 0.00 | 9.25M | 5.06M | 3.98M | 3.66M | 6.64M | 397.00K | 505.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 61.49M | 9.25M | 5.06M | 3.98M | 3.66M | 6.64M | 397.00K | 505.00K |
| Other Expenses | 30.41M | 79.21M | 62.04M | 55.51M | 27.03M | 32.93M | 20.17M | 16.54M |
| Operating Expenses | 215.74M | 183.63M | 163.83M | 124.15M | 66.22M | 56.52M | 33.39M | 29.18M |
| Cost & Expenses | 215.74M | 183.63M | 163.83M | 124.15M | 66.22M | 56.52M | 33.39M | 29.18M |
| Interest Income | 14.13M | 8.91M | 3.06M | 4.58M | 5.54M | 1.26M | 564.00K | 206.00K |
| Interest Expense | 382.00K | 0.00 | 333.00K | 240.00K | 263.00K | 133.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 885.00K | 2.65M | 2.70M | 2.72M | 2.06M | 601.00K | 534.00K | 489.00K |
| EBITDA | -214.85M | -164.90M | -161.69M | -117.59M | -58.84M | -55.92M | -32.86M | -28.69M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -215.74M | -183.63M | -163.83M | -124.15M | -61.60M | -56.52M | -33.39M | -29.18M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 26.50M | 15.84M | -890.00K | 3.59M | 5.05M | 1.24M | 561.00K | 203.00K |
| Income Before Tax | -189.24M | -167.79M | -164.72M | -120.55M | -61.17M | -55.28M | -32.83M | -28.98M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -20.89M | 2.04M | -3.83M | -5.32M | -1.38M | -561.00K | -204.00K |
| Net Income | -189.24M | -146.90M | -166.76M | -116.72M | -55.85M | -53.90M | -32.27M | -28.78M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -5.50 | -4.29 | -5.15 | -3.86 | -2.44 | -3.36 | -2.09 | -1.86 |
| EPS Diluted | -5.50 | -4.29 | -5.15 | -3.86 | -2.44 | -3.36 | -2.09 | -1.86 |
| Weighted Avg Shares Out | 34.40M | 34.25M | 32.37M | 30.26M | 22.93M | 16.02M | 15.44M | 15.44M |
| Weighted Avg Shares Out (Dil) | 34.40M | 34.25M | 32.37M | 30.26M | 22.93M | 16.02M | 15.44M | 15.44M |
No news found for: ULTI.OL
Source: https://incomestatements.info
Category: Stock Reports